4SC

4SC AG is a biotech company in a terminal wind-down phase. Its sole clinical asset, Resminostat, failed to gain regulatory approval from the EMA, leading to the cessation of all R&D and operational activities. The company is currently executing capital measures, including a reduction to zero and subsequent increase, resulting in the expiry of old shares and its delisting, effectively marking the end of its existence as a drug development entity.

Historically focused on small molecule epigenetic modulators, specifically histone deacetylase (HDAC) inhibitors. Platform is no longer active.

The company has ceased all competitive activities. It no longer participates in the oncology or epigenetic drug development landscape.